New Stock News | Chongqing Zhifei Biological Products Co., Ltd. (SHA: 688319) Hong Kong IPO Prospectus Has Expired

Chengdu Olymvax Biopharmaceutical Co., Ltd. (ticker: Olymvax, 688319.SH) submitted its Hong Kong IPO prospectus on November 25, 2025. The application lapsed on May 25, 2026, after six months, with China Securities as the sole sponsor at the time of filing.

Zhitong FinanceMay 26 10:41

Ouling Bio (688319.SH): Taichang Group has not reduced its stake in the company.

Gelonghui, May 25 — Ouhai Bio (SHA: 688319) announced that the company recently received a letter from Taichang Group titled 'Notification on Completion of Share Reduction Plan,' stating that it did not reduce any shares of the company during the period from February 26, 2026, to May 25, 2026, and the time window for this share reduction plan has now expired.

Gelonghui FinanceMay 25 18:57

Express News | The concept of innovative drugs rebounded amid volatility, with Tonghua Jinma approaching the upper limit of the price increase.

BreakingsMay 6 09:53

Oulin Bio: First Quarter Report for 2026 of Chengdu Oulin Biotechnology Co., Ltd.

SZSIApr 30 00:00 · Announcements

First Quarter Report of Chengdu Oulin Biotechnology Co., Ltd. for 2026

SZSIApr 30 00:00 · Announcements

Oulin Bio (688319.SH) reported a net profit of 27.19 million yuan in the first quarter, representing a year-on-year increase of 484.36%.

According to the financial news platform, on April 29, Oulin Bio (688319.SH) released its Q1 2026 earnings report, showing that the company achieved operating revenue of 158 million yuan in the first quarter, representing a year-on-year increase of 80.37%; net profit attributable to shareholders of 27.19 million yuan, reflecting a year-on-year surge of 484.36%; and non-GAAP net profit attributable to shareholders of 23.28 million yuan, marking a year-on-year growth of 311.18%.

Gelonghui FinanceApr 29 18:12